Sinopharm Group Co Stock Fundamentals
| X2S Stock | EUR 2.60 0.10 4.00% |
Sinopharm Group Co fundamentals help investors to digest information that contributes to Sinopharm Group's financial success or failures. It also enables traders to predict the movement of Sinopharm Stock. The fundamental analysis module provides a way to measure Sinopharm Group's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sinopharm Group stock.
Sinopharm |
Sinopharm Group Co Company Shares Outstanding Analysis
Sinopharm Group's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Sinopharm Group Shares Outstanding | 1.34 B |
Most of Sinopharm Group's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sinopharm Group Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, Sinopharm Group Co has 1.34 B of shares currently outstending. This is much higher than that of the Healthcare sector and significantly higher than that of the Medical Distribution industry. The shares outstanding for all Germany stocks is 134.66% lower than that of the firm.
Sinopharm Group Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Sinopharm Group's current stock value. Our valuation model uses many indicators to compare Sinopharm Group value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Sinopharm Group competition to find correlations between indicators driving Sinopharm Group's intrinsic value. More Info.Sinopharm Group Co is rated first in return on equity category among its peers. It is rated first in return on asset category among its peers reporting about 0.28 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Sinopharm Group Co is roughly 3.62 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Sinopharm Group's earnings, one of the primary drivers of an investment's value.Sinopharm Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sinopharm Group's direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sinopharm Group could also be used in its relative valuation, which is a method of valuing Sinopharm Group by comparing valuation metrics of similar companies.Sinopharm Group is currently under evaluation in shares outstanding category among its peers.
Sinopharm Fundamentals
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0364 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | 0.04 % | |||
| Current Valuation | 15.96 B | |||
| Shares Outstanding | 1.34 B | |||
| Shares Owned By Insiders | 0.01 % | |||
| Shares Owned By Institutions | 50.99 % | |||
| Price To Earning | 6.10 X | |||
| Price To Book | 0.89 X | |||
| Price To Sales | 0.01 X | |||
| Revenue | 521.05 B | |||
| Gross Profit | 44.05 B | |||
| EBITDA | 20.76 B | |||
| Net Income | 7.76 B | |||
| Cash And Equivalents | 34.36 B | |||
| Cash Per Share | 11.01 X | |||
| Total Debt | 8.42 B | |||
| Debt To Equity | 0.93 % | |||
| Current Ratio | 1.29 X | |||
| Book Value Per Share | 21.01 X | |||
| Cash Flow From Operations | 9.31 B | |||
| Earnings Per Share | 0.35 X | |||
| Price To Earnings To Growth | 50.46 X | |||
| Number Of Employees | 113.23 K | |||
| Beta | 0.72 | |||
| Market Capitalization | 7.98 B | |||
| Total Asset | 335.41 B | |||
| Z Score | 1.0 | |||
| Annual Yield | 0.05 % | |||
| Five Year Return | 2.38 % | |||
| Net Asset | 335.41 B | |||
| Last Dividend Paid | 0.75 |
About Sinopharm Group Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sinopharm Group Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sinopharm Group using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sinopharm Group Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the Peoples Republic of China. The company was founded in 2003 and is headquartered in Shanghai, the Peoples Republic of China. SINOPHARM GRP operates under Medical Distribution classification in Germany and is traded on Frankfurt Stock Exchange. It employs 108370 people.
Currently Active Assets on Macroaxis
Other Information on Investing in Sinopharm Stock
Sinopharm Group financial ratios help investors to determine whether Sinopharm Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sinopharm with respect to the benefits of owning Sinopharm Group security.